This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Opexa Executes Service Agreement With Blood Group Alliance, Inc.

Stocks in this article: OPXA

Opexa Therapeutics, Inc. (NASDAQ: OPXA), a company developing Tovaxin®, a novel T-cell therapy for multiple sclerosis (MS), announced today that the Company has executed an agreement with Blood Group Alliance, Inc. (BGA), a cooperative of community blood centers, to provide blood collection services to support Opexa’s clinical studies, including a planned Phase III study of Tovaxin in patients with Relapsing-Remitting MS.

This agreement will substantially enhance the overall process for the production of Tovaxin as the first step in the manufacturing process is obtaining a unit of whole blood from the patient. With BGA’s North American footprint extending throughout the United States and into Canada, patients in Opexa’s clinical trials will have access to a very broad network of treatment centers ensuring improved efficiency in blood collection. BGA has agreed to manage the collection of the blood and ship the units to Opexa’s facility for further manufacturing of the Tovaxin product. Opexa recently announced a similar agreement with the American Red Cross. In combination, these two groups provide Opexa with access to over 90% of the blood procurement centers in the United States. With these agreements, Opexa has now put into place a strong network of procurement locations nationwide which provide feasibility for commercialization as well as an excellent supply chain for Opexa’s future clinical studies.

"The feasibility of procurement for the clinical manufacture of Tovaxin has been solidified with the execution of these agreements,” commented Jaye Thompson, Ph.D., Senior Vice President, Clinical Development and Regulatory Affairs of Opexa. “We are pleased to be associated with BGA and their network of community blood centers. Our partnership will allow Opexa great flexibility to utilize investigational sites in almost any location for future Tovaxin studies. This unlimited access will be valuable for our patients and physicians. In addition, these contracts should result in a stable and reduced cost of goods in the manufacture of Tovaxin.”

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Jim Cramer and Stephanie Link reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

Jim Cramer's protégé, David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
Try it NOW
Try it NOW
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

Jim Cramer's protégé, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 17,672.60 -141.38 -0.79%
S&P 500 2,051.82 -11.33 -0.55%
NASDAQ 4,757.8790 +7.4820 0.16%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs